On Friday, Immutep Limited (NASDAQ:IMMP) received a positive assessment from CapitalOne, as the firm initiated coverage with an Overweight rating and a price target of $10.00. The biotechnology company, which specializes in novel cancer treatments, is currently advancing trials for its lead product, eftilagimod alpha (efti), across five different oncology indications.
Efti is under evaluation in combination with standard of care therapies for various cancers, including non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), HR+/HER2- metastatic breast cancer (mBC), soft tissue sarcoma, and urothelial carcinoma. Notably, in a first-line treatment setting for NSCLC, efti combined with pembrolizumab has demonstrated a significant increase in median overall survival (OS) compared to the standard pembrolizumab and chemotherapy regimen, with results showing 35.5 months for efti/pembrolizumab versus 18.9 to 23.3 months for the latter.
The promising results have also been replicated in the HNSCC arm of the TACTI-002 study. Additionally, a combination of efti with chemotherapy has shown potential benefits in late-line metastatic breast cancer. These findings have positioned Immutep to advance towards pivotal trials in NSCLC and mBC in the near term.
CapitalOne's commentary highlighted the robustness of the clinical data and the company's preparation for pivotal studies. The firm has conservatively estimated peak sales for efti to reach approximately $4.3 billion in 2040, focusing on its application in mBC, NSCLC, and HNSCC. This forecast underscores the potential market opportunity for Immutep's efti in the oncology space.
Immutep's progress in its clinical programs and the optimistic outlook from CapitalOne suggest a noteworthy advancement in the development of new cancer therapies, with efti at the forefront of this innovation. The company's focus on bringing efti to pivotal trials signifies a critical step towards potential commercialization and addressing unmet medical needs in oncology.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.